Analyst: This Penny Stock Could Quadruple

NTGN stock has been sliding in recent weeks

Jun 4, 2019 at 12:20 PM
facebook twitter linkedin

Mizuho initiated coverage on Neon Therapeutics Inc (NASDAQ:NTGN) with a "buy" rating and $21 price target -- a 333% premium to last night's close. The brokerage firm said NTGN's low share price is a result of confusion around neoantigens science, which studies a new cancer therapy.

LifeSci Capital also chimed in, saying the cancer researcher's Phase I neoantigen vaccine study could be "best-in-class," should results of the trial remain consistent. This follows positive data for Neon Therapeutics' peer Genocea Biosciences, which sent its stock gapping higher on Monday.

Analysts are already overwhelmingly bullish on NTGN stock, with 100% of those in coverage maintaining a "buy" or better rating. Plus, the average 12-month price target sits all the way up at $19.13.

Looking closer at the charts, Neon Therapeutics has been in a channel of lower highs and lows since its mid-April peak at $7.51, under pressure from its 20-day moving average. While the shares have recovered since their late-May low at $4.50, they are struggling to break out above their 10-day moving average and year-to-date breakeven mark at $5.03, last seen up 4.3% at $5.06.

ntgn stock daily price chart on june 4


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners